Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients

NCT02576093 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis, Atopic

Interventions

DRUG: 0.1% WOL071-007
DRUG: 0.3% WOL071-007
DRUG: 1.0% WOL071-007
DRUG: Placebo of WOL071-007

Sponsor

Dr. August Wolff GmbH & Co. KG Arzneimittel

Collaborators

[object Object]